The successful company from Greifswald, CHEPLAPHARM Arzneimittel GmbH, continues to grow: 50 new employees have been recruited in the past eight months.
Reasons for this strong growth are newly acquired brand products such as XENICAL® and DILATREND®, which are distributed worldwide in more than 120 countries.
Up to 90 percent of CHEPLAPHARM’s new employees are graduates from University, mostly working in the fields of drug approval, CMC (Chemistry, Manufacturing and Controls), drug safety and quality assurance. However, the purchasing, IT and export teams have also been bolstered with highly qualified specialists.
“The project pipeline is absolutely brimming. We continue to see growth. I am pleased to be in a position to provide many, for the most part young people, with a professional career within in our local area,” proudly announced Sebastian F. Braun (CEO).
Founded in July 1998, CHEPLAPHARM was able to grow continuously and develop from a start-up with just three employees and an annual turnover of 600,000 euros to one of the largest medium-sized pharmaceutical companies in Germany today. In 2017, it is the company’s plan to notch up an annual turnover of 237 million euros, doubling its turnover from the previous year. CHEPLAPHARM currently employs around 135 people.
CHEPLAPHARM Arzneimittel GmbH | Ziegelhof 24 | 17489 Greifswald | presse(at)cheplapharm.com